Genmab A/S (GEN.CO) Announces Duobody And Hexabody Platform Collaboration With Undisclosed Biotechnology Company
6/4/2014 9:23:06 AM
Copenhagen, Denmark; June 4, 2014 – Genmab A/S (OMX: GEN), together with its subsidiary, Genmab B.V., announced today a research collaboration with an undisclosed Biotechnology company which would use and evaluate Genmab’s proprietary antibody technologies, the DuoBody and HexaBody platforms.
Help employers find you! Check out all the jobs and post your resume.
comments powered by